IMRT Best for Locally Advanced NSCLC, Study Suggests Technique reduces risk of severe lung toxicity and radiation to the heart compared with 3D-CRT Sep 13, 2023
Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLC Confirmed responses reached 29.8% in heavily pretreated patients Sep 13, 2023
Study Questions Use of Aggressive Surgery in Early Mesothelioma Randomized data suggest surgery increases risk of death by 28% over first 42 months Sep 12, 2023
Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancer Osimertinib plus chemotherapy improved PFS by nearly 9 months versus targeted agent alone Sep 12, 2023
First-Line Triplet Yields 'Striking' OS Result in Extensive-Stage SCLC Median overall survival reached 19.3 months in Chinese trial Sep 11, 2023
How the Chemotherapy Shortage Is Affecting Frontline Clinicians "How are we here in 2023 having some of these discussions?" bemoans gynecologic cancer expert Sep 08, 2023 video
Novel KRAS Inhibitor Leads to Durable Responses in Multiple Tumor Types More than half of patients with NSCLC, more than a third of those with CRC responded to divarasib Aug 23, 2023
Removing Race-Corrected Pulmonary Function Tests May Alter Lung Cancer Care Path to eliminating these tests, while crucial, will be challenging, researchers say Aug 16, 2023
Multi-Cancer Early Detection: 20th-Century Fiction Becomes Reality These tests could soon become a valuable addition to current cancer screening tools Aug 01, 2023
Immunotherapy Added to SABR Improves Event-Free Survival in Early NSCLC Approach is "potentially practice-changing," editorialist says Jul 20, 2023
Some NSCLC Patients on ICI Therapy Fare Worse With Proton Pump Inhibitor Use But PFS, OS longer with ICIs plus chemotherapy among patients treated with PPIs Jul 11, 2023
Hooray! A Clearer Estimate of Your Risk for Death Is Here Researchers do the legwork to incorporate smoking status into NCI's "Know Your Chances" website Jun 09, 2023
TTFields Therapy Yields OS Improvement in Second-Line NSCLC However, device was not tested alongside current standard of care, expert points out Jun 08, 2023
Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLC "Immediate changes" needed to patient care to avoid unnecessary toxicity, says ASCO expert Jun 07, 2023
Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Years Retrospective study finds no difference in OS between patients who stop and those who continue Jun 06, 2023
New Data in NSCLC Bolster Support for Perioperative Immunotherapy EFS benefit with pembrolizumab in KEYNOTE-671, but no OS benefit "yet," says investigator Jun 05, 2023
New Standard in Operable EGFR-Positive Lung Cancer "We should firmly close the door on one-size-fits-all treatment," says ASCO expert Jun 04, 2023
Lung Cancer Screening Results Influence Follow-Up Adherence Study suggests groups to target for enhanced outreach to encourage regular screening May 25, 2023
'Potential' New Option for Operable NSCLC Adding perioperative durvalumab to neoadjuvant chemo improved pCR rates, event-free survival Apr 17, 2023
FDA Allows Lower Risk Designation for Snuff Product The brand joins a limited few granted modified risk tobacco claims Mar 16, 2023
AI Tool Forecasts Lung Cancer Risk From a Single CT Scan Experts give high marks to performance of "Sybil" in predicting disease over 6 years Feb 07, 2023
Risk Model-Based Lung Cancer Screening More Cost-Effective Than USPSTF Recs Risk prediction models more sensitive than age-, smoking history-based methods Feb 07, 2023
Bispecific Antibody Active in Relapsed/Refractory Small Cell Lung Cancer A majority of patients obtained disease control with tarlatamab; responses proved durable Feb 01, 2023
Immunotherapy Survival Gains 'Less Impressive' in Older Lung Cancer Patients Study finds median OS improvement of just 1 month for patients 75 and older Jan 26, 2023
Xeljanz Cancer Risks Detailed New paper provides full results from ORAL Surveillance trial Dec 07, 2022
Lung Cancer Survival High for Patients With Early, Screen-Detected Tumors Two decades of I-ELCAP follow-up data show 80% lung cancer-specific survival rate Nov 28, 2022
Lung Cancer Screening Programs Hit the Mark on Eligibility Criteria However, adherence to follow-up screening is "suboptimal" Oct 10, 2022
FDA Grants First Tumor-Agnostic Approval for RET Fusion-Positive Cancers Selpercatinib approved for advanced or metastatic solid tumors that progress on systemic therapy Sep 22, 2022
KRAS Inhibitor Tops Docetaxel for Previously Treated NSCLC "New second-line standard" in KRAS G12C-mutant disease, says study investigator Sep 13, 2022
Survival Bump in Unfit NSCLC With First-Line Immunotherapy Atezolizumab doubles OS at 2 years versus chemotherapy in those ineligible for platinum doublets Sep 12, 2022
Combination Therapy Shows Promise for NSCLC That Progresses on Osimertinib About half of patients responded to tepotinib plus osimertinib, but efficacy ceiling persists Sep 12, 2022
Locking Down a Link Between Pollution and EGFR-Mutated Lung NSCLC Study also shed lights on what may lead to lung cancer in never smokers Sep 11, 2022
Study: Microwave Ablation for Lung Nodules Effective as Last Resort Good option for patients who can't have surgery or radiotherapy, surgeon says Sep 08, 2022
'Clinically Meaningful' Improvement in SCLC Patients With Pembrolizumab/Chemo Combo Long-term follow-up shows continued survival benefit as first-line treatment Aug 11, 2022
Triple Therapy Continues to Impress in Metastatic NSCLC With High-Risk Mutations Meaningful survival boosts in POSEIDON trial of front-line durvalumab, tremelimumab, and chemo Aug 10, 2022
Survey: 77% of Women With Lung Cancer Report Sexual Dysfunction Results show need to integrate sexual health into care, researcher says Aug 09, 2022
Neodjuvant Chemoimmunotherapy Takes Another Step Forward in Stage IIIA-B NSCLC Phase II trial supports neoadjuvant nivolumab plus chemotherapy Aug 09, 2022
New Data Bolster Atezolizumab as Adjuvant Tx in NSCLC Overall survival benefit now demonstrated Aug 09, 2022
Low-Dose Sotorasib 'Lead-in' Strategy Promising in NSCLC Subset Early phase results set the stage for KRAS/immune-targeted combo as potential first-line option Aug 08, 2022
Sublobar Resection the 'New Standard of Care' in Small-Sized NSCLC? Large randomized study shows non-inferiority to lobectomy Aug 08, 2022
